Merck & Co., Inc. Release: Expanded Access Program For MK-0518, An Investigational HIV Integrase Inhibitor, Established For Patients With Limited Available Treatment Options; Worldwide Access Program Will Be Conducted Along With Phase III Studies

TORONTO--(BUSINESS WIRE)--Aug. 17, 2006--A worldwide expanded access program for HIV/AIDS patients with limited or no treatment options was announced today by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., with respect to its investigational HIV integrase inhibitor, MK-0518, now in Phase III development. Program enrollment will begin in the next few months, pending regulatory review and approvals.